Combination Therapy
AssigneesMedivation Prostate Therapeutics, Inc., Astellas Pharma Inc.
InventorsJacqueline Gibbons, Joyce Mordenti, Michiel De Vries, Walter Krauwinkel, Taoufik Ouatas
Life of this patent
Estimating the term…
Abstract
This disclosure provides a dosage regimen for co-administration of 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide and a strong CYP3A4 inducer.
Claims4
A method of treating cancer in a patient to whom a CYP3A4 inducer is administered, comprising administering to the patient a therapeutically effective dose of 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7- iazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide and a CYP3A4 inducer, wherein the therapeutically effective dose of 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide is 200-300 mg per day.
Dependencies are inferred from the claim text.